No Data
No Data
Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After...
Progressive on Track for Longest Losing Streak Since September 2021 -- Data Talk
Progressive Hits 8-week Low
Optimistic Buy Rating on Progressive Leasing: Navigating Challenges With Strategic Management and Revised Revenue Guidance
Goldman Sachs: The Progressive Corporation (NYSE:PGR) Is A Stock Both Hedge & Mutual Funds Love
Progressive Insurance Allocates Over $3 Million to Support Disaster Relief Efforts